Novavax (NVAX)
(Delayed Data from NSDQ)
$4.09 USD
+0.14 (3.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.07 -0.02 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Company Summary
Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company’s vaccines to enhance immune response.
Novavax developed its novel coronavirus vaccine, a protein-based vaccine that utilizes the company’s proprietary nanoparticle technology. The company is currently marketing different versions of its COVID-19 vaccine — one marketed in partnership with the Serum Institute of India (Serum) under the trade name Covovax and another version produced by Novavax that ...
Company Summary
Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company’s vaccines to enhance immune response.
Novavax developed its novel coronavirus vaccine, a protein-based vaccine that utilizes the company’s proprietary nanoparticle technology. The company is currently marketing different versions of its COVID-19 vaccine — one marketed in partnership with the Serum Institute of India (Serum) under the trade name Covovax and another version produced by Novavax that is marketed under the trade name Nuvaxovid. In the United States, the vaccine is marketed as Novavax COVID-19 Vaccine, Adjuvanted.
Currently, Novavax’s COVID-19 vaccine is authorized for use in the United States as a two-dose primary series in adults and adolescents aged 12 years and older. The vaccine is also authorized for use as a booster dose in adults. The vaccine is also approved/authorized for use in multiple markets like Australia, Canada, Europe, India and Indonesia.
Novavaxhas developed a recombinant quadrivalent seasonal influenza vaccine candidate (formerly NanoFlu). Management is also evaluating the combination of the vaccine with the COVID-19 vaccine, which the company is looking to advance to late-stage development before 2024-end.
To rationalize its manufacturing footprint and reduce costs, the company has undertaken multiple restructuring initiatives. These initiatives have not only helped the company in bringing down its current costs but also reduced short-term liabilities by around $800 million.
In 2023, the company generated $983.7 million in total revenues, down 50% year over year.
General Information
Novavax, Inc
700 Quince Orchard Road
GAITHERSBURG, MD 20878
Phone: 240-268-2000
Fax: 240-268-2100
Email: ir@novavax.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.04 |
Current Year EPS Consensus Estimate | -0.83 |
Estimated Long-Term EPS Growth Rate | 52.20 |
Exp Earnings Date | 5/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 3.95 |
52 Week High | 11.36 |
52 Week Low | 3.53 |
Beta | 1.59 |
20 Day Moving Average | 3,605,512.75 |
Target Price Consensus | 15.40 |
4 Week | -14.44 |
12 Week | 4.07 |
YTD | -14.79 |
4 Week | -11.85 |
12 Week | 1.19 |
YTD | -20.31 |
Shares Outstanding (millions) | 139.95 |
Market Capitalization (millions) | 572.41 |
Short Ratio | NA |
Last Split Date | 5/10/2019 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 36.84% |
vs. Previous Quarter | -14.29% |
vs. Previous Year | -18.48% |
vs. Previous Quarter | 55.81% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | 0.58 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | -32.63 |
9/30/23 | -30.74 |
3/31/24 | NA |
12/31/23 | 0.70 |
9/30/23 | 0.69 |
3/31/24 | NA |
12/31/23 | 0.67 |
9/30/23 | 0.64 |
3/31/24 | NA |
12/31/23 | -55.41 |
9/30/23 | -52.29 |
3/31/24 | NA |
12/31/23 | -55.41 |
9/30/23 | -52.29 |
3/31/24 | NA |
12/31/23 | -55.20 |
9/30/23 | -52.47 |
3/31/24 | NA |
12/31/23 | -6.04 |
9/30/23 | -5.71 |
3/31/24 | NA |
12/31/23 | 8.14 |
9/30/23 | 9.04 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |